Waltham, MA and Canoga Park, CA 7/16/12—Thermo Fisher Scientific has agreed to acquire One Lambda for $925 million in cash, subject to post-closing adjustment. One Lambda provides diagnostic tests that are used by transplant centers for tissue typing, primarily to determine the compatibility of donors and recipients pre-transplant and to detect the presence of antibodies that can lead to transplant rejection. One Lambda had 2011 revenues of $182 million. “One Lambda gives us access to the attractive transplant diagnostics market and complements our existing immunosuppressant monitoring assays,” commented Thermo President and CEO Marc N. Casper. “It also offers the opportunity to leverage our global commercial infrastructure to serve growing transplant needs in emerging markets.” The acquisition is expected to be immediately accretive upon close and to add $0.09–$0.11 to 2013 adjusted EPS. The transaction is expected to close in the fourth quarter.